<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36504406</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48&#x2009;weeks of treatment.</ArticleTitle><Pagination><StartPage>124</StartPage><EndPage>129</EndPage><MedlinePgn>124-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27768</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). An oral suspension formulation of edaravone was recently approved by the United States Food and Drug Administration for use in patients with ALS. This study assessed the safety and tolerability of oral edaravone.</AbstractText><AbstractText Label="METHODS">This global, open-label, phase 3 study evaluated the long-term safety and tolerability of oral edaravone in adults with ALS who had a baseline forced vital capacity &#x2265;70% of predicted and disease duration &#x2264;3&#xa0;y. The primary safety analysis was assessed at weeks 24 and 48. Patients received a 105-mg dose of oral edaravone in treatment cycles replicating the dosing of IV edaravone.</AbstractText><AbstractText Label="RESULTS">The study enrolled 185 patients (64.3% male; mean age, 59.9&#xa0;y; mean disease duration, 1.56&#x2009;y). The most common treatment-emergent adverse events (TEAEs) at week 48 were fall (22.2%), muscular weakness (21.1%) and constipation (17.8%). Serious TEAEs were reported by 25.9% of patients; the most common were worsening ALS symptoms, dysphagia, dyspnea, and respiratory failure. Twelve TEAEs leading to death were reported. Forty-six (24.9%) patients reported TEAEs that were considered related to study drug; the most common were fatigue, dizziness, headache, and constipation. Sixteen (8.6%) patients discontinued study drug due to TEAEs. No serious TEAEs were related to study drug.</AbstractText><AbstractText Label="DISCUSSION">This study indicated that oral edaravone was well tolerated during 48&#x2009;wk of treatment, with no new safety concerns identified.</AbstractText><CopyrightInformation>&#xa9; 2022 Mitsubishi Tanabe Pharma America, Inc and The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research and ALS Clinic, Montreal Neurological Institute and Hospital, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0001-8365-6707</Identifier><AffiliationInfo><Affiliation>Neurological Sciences Department, University of Nebraska Medical Center, Lincoln, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Hiide</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yoshino Neurology Clinic, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NEMO Clinical Center, Fondazione Serena Onlus, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic for Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selness</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical and Technical Operations, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bidani</LastName><ForeName>Sachin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Development, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research &amp; Development, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakata</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Global Products Management Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salah</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Affairs, Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3051-3953</Identifier><AffiliationInfo><Affiliation>Medical Affairs, Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wamil</LastName><ForeName>Art</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology, Medical Science, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Drug Safety, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="Y">Edaravone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">edaravone</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36504406</ArticleId><ArticleId IdType="pmc">PMC10107134</ArticleId><ArticleId IdType="doi">10.1002/mus.27768</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Center for Drug Evaluation and Research (CDER)
. Rilutek (Riluzole) Marketing Approval. 2017. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=072792. Accessed November 22, 2022.</Citation></Reference><Reference><Citation>
Center for Drug Evaluation and Research (CDER)
. Radicava (Edaravone) Injection Approval Letter. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000Approv.pdf. Accessed November 22, 2022.</Citation></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler. 2006;7(4):241&#x2010;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of efficacy and safety of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI&#x2010;186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone ALS 17 Study Group . Exploratory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled extension study of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):20&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872918</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone ALS 18 Study Group . Exploratory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl 1):40&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872915</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C, Heiman&#x2010;Patterson T, Kittrell P, et al. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):605&#x2010;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">31364409</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nishimura Y, Shiide Y, et al. Evaluation of pharmacokinetics, safety, and drug&#x2010;drug interactions of an oral suspension of edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10(10):1174&#x2010;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518673</ArticleId><ArticleId IdType="pubmed">33704925</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nishimura Y, Shiide Y, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188&#x2010;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518908</ArticleId><ArticleId IdType="pubmed">33955162</ArticleId></ArticleIdList></Reference><Reference><Citation>
ClinicalTrials.gov
. Safety Study of Oral Edaravone Administered in Subjects with ALS. NCT04165824. National Institutes of Health, U.S. National Library of Medicine; 2022. https://www.clinicaltrials.gov/ct2/show/NCT04165824. Accessed November 22, 2022.</Citation></Reference><Reference><Citation>Radicava&#xae; (Edaravone) Injection and Radicava ORS&#xae; (Edaravone) Oral Suspension Prescribing Information. Mitsubishi Tanabe Pharma Corporation; 2022.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia&#x2010;suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266&#x2010;1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate&#x2010;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2010;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et al. Masitinib as an add&#x2010;on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1&#x2013;2):5&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Genge A, van den Berg LH, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 2 trial. Lancet Neurol. 2017;16(3):208&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Schuster J, Dorst J, et al. Safety and efficacy of rasagiline as an add&#x2010;on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled, phase 2 trial. Lancet Neurol. 2018;17(8):681&#x2010;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994;3(10):1757&#x2010;1761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. PLoS One. 2016;11(10):e0164625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>